PCSK9: A Potential Therapeutic Target for Sepsis

PCSK9: A Potential Therapeutic Target for Sepsis

Sepsis is a life-threatening organ dysfunction syndrome caused by a dysregulated host response to infection. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is often upregulated in the presence of sepsis and infectious diseases. In sepsis, PCSK9 degraded the low-density lipoprotein cholesterol...

Full description

Bibliographic Details
Main Authors:	Yuan Yuan, Wei Wu, Shanshan Sun, Yi Zhang, Zhi Chen
Format:	Article
Language:	English
Published:	Hindawi Limited 2020-01-01
Series:	Journal of Immunology Research
Online Access:	http://dx.doi.org/10.1155/2020/2687692

Similar Items

Phage display for targeting PCSK9
by: Nicola Ferri
Published: (2021-03-01)

PCSK9 and its clinical importance with the new therapeutic targets against dyslipidemia
by: Carlos Eduardo dos Santos Ferreira, et al.

Potential of PCSK9 as a new target for the management of LDL cholesterol
by: Mombelli G, et al.
Published: (2015-07-01)

Post-translational regulation of the low-density lipoprotein receptor : PCSK9 as a therapeutic target
by: Duff, Christopher
Published: (2010)

The PCSK9 decade
by: Gilles Lambert, et al.
Published: (2012-12-01)

PCSK9: A New Target for Lipid-Lowering Therapy
by: Nutjaree Jeenduang
Published: (2014-04-01)

The Pathogenesis of Sepsis and Potential Therapeutic Targets
by: Min Huang, et al.
Published: (2019-10-01)

Identifying functional single nucleotide polymorphisms in two candidate genes (PROC and PCSK9) in sepsis
by: Thain, Katherine Roberta
Published: (2013)

Identifying functional single nucleotide polymorphisms in two candidate genes (PROC and PCSK9) in sepsis
by: Thain, Katherine Roberta
Published: (2013)

Identifying functional single nucleotide polymorphisms in two candidate genes (PROC and PCSK9) in sepsis
by: Thain, Katherine Roberta
Published: (2013)

Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis
by: Amir Abbas Momtazi-Borojeni, et al.
Published: (2019-12-01)

Targeting PCSK9: a promising adjuvant strategy in cancer immunotherapy
by: Catarina R. Almeida, et al.
Published: (2021-03-01)

PCSK9: A Key Target for the Treatment of Cardiovascular Disease (CVD)
by: Saeideh Sobati, et al.
Published: (2020-08-01)

New developments in atherosclerosis: clinical potential of PCSK9 inhibition
by: Giunzioni I, et al.
Published: (2015-08-01)

Microglia: A Potential Therapeutic Target for Sepsis-Associated Encephalopathy and Sepsis-Associated Chronic Pain
by: Yi Li, et al.
Published: (2020-11-01)

PCSK9 and the Gut-Liver-Brain Axis: A Novel Therapeutic Target for Immune Regulation in Alcohol Use Disorder
by: Ji Soo Lee, et al.
Published: (2021-04-01)

Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly
by: Ranheim Trine, et al.
Published: (2007-03-01)

PCSK9 monoclonal antibodies: An overview
by: Rasha Kaddoura, et al.
Published: (2020-01-01)

Naturally Occurring PCSK9 Inhibitors
by: Maria Pia Adorni, et al.
Published: (2020-05-01)

PCSK9 Antibodies for the Treatment of Hypercholesterolemia
by: Ioanna Gouni-Berthold, et al.
Published: (2014-12-01)

PCSK9 function and physiology*1
by: Andrew S. Peterson, et al.
Published: (2008-06-01)

PCSK9 and cancer: Rethinking the link
by: Khadijeh Mahboobnia, et al.
Published: (2021-08-01)

Pleiotropic Effects of PCSK-9 Inhibitors
by: Marcin Basiak, et al.
Published: (2021-03-01)

Expression of PCSK9 in Hepatocellular Carcinoma
by: Bhat, Mamatha
Published: (2012)

Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts
by: My-Anh Nguyen, et al.
Published: (2014-02-01)

Comparative quantitative systems pharmacology modeling of anti-PCSK9 therapeutic modalities in hypercholesterolemia[S]
by: Victor Sokolov, et al.
Published: (2019-09-01)

microRNA-483 ameliorates hypercholesterolemia by inhibiting PCSK9 production
by: Jianjie Dong, et al.
Published: (2020-12-01)

Autophagy: A Potential Therapeutic Target for Reversing Sepsis-Induced Immunosuppression
by: Chao Ren, et al.
Published: (2017-12-01)

Reduction in PCSK9 levels induced by anacetrapib: an off-target effect?1
by: Philip J. Barter, et al.
Published: (2015-11-01)

The Role and Mechanism of Pyroptosis and Potential Therapeutic Targets in Sepsis: A Review
by: Xiangtao Zheng, et al.
Published: (2021-07-01)

PCSK9 inhibitors as a therapy for hypercholesterolemia
by: Nofal, Maia
Published: (2016)

LDL-cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid-lowering therapy
by: Hamasaki, M., et al.
Published: (2021)

Trafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal Domain.
by: Steve Poirier, et al.
Published: (2016-01-01)

PCSK9 loss-of-function variants and risk of infection and sepsis in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort.
by: Kellie A Mitchell, et al.
Published: (2019-01-01)

Impact of PCSK9 loss-of-function genotype on 1-year mortality and recurrent infection in sepsis survivorsResearch in context
by: Kelly Roveran Genga, et al.
Published: (2018-12-01)

Development of Inhibitors of Human PCSK9 as Potential Regulators of LDL-Receptor and Cholesterol
by: Alghamdi, Rasha Hassen
Published: (2014)

Editorial: PCSK9: Importance in Physiology and Pathophysiology
by: Rainer Schulz, et al.
Published: (2021-07-01)

New lipid therapies: PCSK9 inhibitors
by: Farah Meah, DO, et al.
Published: (2016-12-01)

LDL Cholesterol, Statins And PCSK 9 Inhibitors
by: Sanjiv Gupta
Published: (2015-09-01)

Cholesterol and stroke: role of PCSK9 inhibitors
by: L. Castilla-Guerra, et al.
Published: (2019-04-01)